NCT04239625View on ClinicalTrials.gov

Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

December 20, 2019

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Stargardt DiseaseStargardt Macular DegenerationStargardt Macular DystrophyAutosomal Recessive Stargardt Disease 1 (ABCA4-related)
Interventions
DRUG

ALK-001

Oral administration of a pill for up to 24 months

Trial Locations (8)

11590

Alkeus Site, Westbury

32601

Alkeus Site, Gainesville

46202

Alkeus Site, Indianapolis

49456

Alkeus Site, Grand Rapids

80045

Alkeus Site, Aurora

85020

Alkeus Site, Phoenix

90095

Alkeus Site, Los Angeles

98383

Alkeus Site, Silverdale

Sponsors
All Listed Sponsors
lead

Alkeus Pharmaceuticals, Inc.

INDUSTRY